ACOG
Alpha Cognition Inc (ACOG)
Healthcare • NASDAQ • $6.10+0.16%
- Symbol
- ACOG
- Exchange
- NASDAQ
- Sector
- Healthcare
- Industry
- Biotechnology
- Price
- $6.10
- Daily Change
- +0.16%
- Market Cap
- $132.82M
- Trailing P/E
- N/A
- Forward P/E
- -12.20
- 52W High
- $11.54
- 52W Low
- $4.50
- Analyst Target
- $16.00
- Dividend Yield
- N/A
- Beta
- 2.39
Alpha Cognition Inc., a biopharmaceutical company, engages in the development of treatments for patients suffering from neurodegenerative diseases in the United States and Canada. The company's commercial development program includes ZUNVEYL oral tablet formulation for treating Alzheimer's disease. Its pre-clinical development programs comprise ZUNVEYL in combination with memantine for the treatment of moderate-to-severe Alzheimer's disease; ALPHA-1062 sublingual formulation; ALPHA-1062 intranasal formulation for the treatment of cognitive impairment with mild traumatic brain injury; and ALPHA-0602, ALPHA-0702, and ALPHA-0802 programs for the treatment of neurodegenerative diseases, including amyotrophic lateral sclerosis disease and spinal muscular atrophy. Alpha Cognition Inc. was founde…
Company websiteResearch ACOG on Stk-Ai
Stk-Ai gives you screening across 100+ fundamental metrics, AI-powered analysis, target predictions, backtested signals, and portfolio tracking — all in one place.
Data shown is for informational purposes only and is not investment advice. Prices and metrics may be delayed.